ÂÜÀòÂÒÂ×

John Hastewell is a biochemist by training, B.A (Oxon), D.Phil. (Ebor), After researching gastrointestinal absorption of pyrimidines, he joined Ciba-Geigy (now Novartis) in 1989, working across research and early development. He moved to Cambridge MA, in 2003, as Head of the Program Office to help create the strategy and build the new NIBR Institutes for Biomedical Sciences, becoming head of the NIBR Biologics Center. In this role he supported the development of the required technologies for all non small molecule therapeutics (antibodies, protein and nucleic acid based). Ultimately as head of Research Cambridge was responsible for preclinical sciences, research analytics, imaging, drug discovery technologies and several Disease Areas. He retired from Novartis in 2018.